Other languages Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
0.8574 ^USD	+0.32%		+6.52%	-9.50%

03-14	Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-14	Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
Kezar Life Sciences Launches Restructuring Program, Cuts Workforce, Names New CEO	23-10-03
Kezar Life Sciences, Inc. Announces Executive Changes	23-10-03
Kezar Life Sciences, Inc. Announces CEO Changes	23-10-03
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway	23-10-03
Sector Update: Health Care Stocks Tick Lower Thursday Morning	23-09-21
Kezar Life Sciences Signs License Agreement With Everest Medicines to Develop, Market Zetomipzomib in Asia	23-09-21
Everest Medicines Enters into Collaboration and License Agreement with Kear Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and Other Asian Markets	23-09-20
Kezar Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Kezar Life Sciences, Inc. Announces Resignation of Christopher Kirk as President and Chief Scientific Officer	23-04-27
Bb Biotech : livello investimento 1* trim al 114%, dividendo di 2,85 franchi	23-04-21
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-14
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-14
Christopher Kirk, Ph.D., President, Chief Scientific Officer and Member of the Board of Directors of Kezar Life Sciences, Inc., Intends to Resign, Effective April 21, 2023	23-02-28
Bivictrix promotes non-executive director to non-executive chair	23-01-06
Kezar Life Sciences, Inc. Presents Positive Complete Results from the Mission Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis At the American College of Rheumatology Convergence 2022	22-11-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Other languages

Filters